argenx - Hits road bump with ADVANCE-SC
*This morning, ARGX announced that ADVANCE-SC missed its primary endpoint, despite previous success for ITP with the IV formulation and a solid underlying biological rationale. *During this afternoon's call, we will collect more input on this setback and the noticeably high placebo response rate (16.2% vs. 5% in ADVANCE), and on filing strategy and commercial impact in the USA , where data from both ADVANCE and ADVANCE-SC studies were requested.*More in general, we want to emphasize that ITP is only 1 of the 15 envisioned indications for Efgartigimod by 2025. The company has been blessed by successes in gMG, ITPArgenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.